Gedea Biotech AB

Gedea Biotech is developing a treatment for vaginal infections that actually works, meaning an effective, antibiotic free and safe treatment for vaginal infections that treats the infection and minimizes the risk of recurrence. Meet one of our colleagues, Eva Norell. I work as Marketing and Communications Manager at Gedea and I have been here on and off for six years now. My background is sales, marketing and project management in the pharmaceutical industry and other organizations in or close to the health care sector. A broad range of experience and skills come in handy in a start-up where you I tackle a variety of tasks each day 😊 During the last week, I have received six emails and messages from women asking about our product pHyph and when it’ll be available in the US or Europe. The week before it was three emails.  The week before that it was five. Women from different parts of the world write to us and tell us about their suffering from bacterial vaginosis and how they cannot live their lives fully, because of recurrent infections. I am very thankful for their messages, because that reminds me that we are doing something very important that will improve lives of millions of women. It makes my workday meaningful. The lengthy timelines in product development can be frustrating. While it’s crucial to be meticulous with medical products, I can’t help but feel eager to launch! I am currently working on a thorough update of our webpage, that will reflect the development stage we are in now. It’s a process to decide how and what to communicate and there is a lot of discussion with my helpful colleagues. #womenshealth #AMR #gedeabiotech

Today Eva Norell from Gedea Biotech AB attended the Nordic-African Women’s Health conference Organized by the Women African Ambassadors in Sweden, Ferring Pharmaceuticals and United Nations Population Fund (UNFPA) at the Ferring headquarters in Copehagen. Topics for the day was innovation in women’s health and antimicrobial resistance. Antimicrobial resistance hits all parts of society; health care, agriculture, economic. There are no sex differentiated data on how AMR hits but women are like to receive antibiotics 27% more often than men, during life. AMR is projected to surpass cancer as the leading cause of death, by 2025. Thank you for the invite to this eye opening event, we are inspired to make a sustainable contribution to women’s health, globally. #amr #womenshealth

This post will be in Swedish beacuse it is about a radio program boradcasted by The Swedish Public Service Radio, Channel 1, Sveriges Radio P1. I "Vetenskapsradion På Djupet"  berättar Luisa Hugerth vid Uppsala universitet hur forskning om de bakterier som bor i kroppen kan hjälpa oss att lindra besvär i underlivet. I programmet slår man ihjäl några myter om underlivshälsa och förmedlar intressant och användbar kunskap om bland annat bakteriell vaginos. Louisa Hugerth är biträdande handledare till Gedeas industridoktorand Emilia Lahtinen vid Karolinska Institutet, vid sidan av handledare Ina Schuppe Koistinen. https://lnkd.in/dHwAYSPk

This post will be in Swedish beacuse it is about a radio program boradcasted by The Swedish Public Service Radio, Channel 1, Sveriges Radio P1. I "Vetenskapsradion På Djupet"  berättar Luisa Hugerth vid Uppsala universitet hur forskning om de bakterier som bor i kroppen kan hjälpa oss att lindra besvär i underlivet. I programmet slår man ihjäl några myter om underlivshälsa och förmedlar intressant och användbar kunskap om bland annat bakteriell vaginos. Louisa Hugerth är biträdande handledare till Gedeas industridoktorand Emilia Lahtinen vid Karolinska Institutet, vid sidan av handledare Ina Schuppe Koistinen. https://lnkd.in/dHwAYSPk

At the Nordic Life Science Days in Malmö, big pharma executives, investors and CEOs of biotech and medtech companies gather for cooperation, work shops, lectures and partnering meetings. Annette Säfholm, CEO at Gedea Biotech AB visits NLS Days to meet with potential partner companies and for trendspotting in life science. And of course to bump in to old friends like Peter Holm from Høibergs.

The development of technology and knowledge regarding the microbiomes present on and in our bodies is progressing rapidly. The microbiome is an environment of bacteria and microorganisms found, for example, in the gastrointestinal tract, in the vagina, or on the skin. The vaginal microbiome is crucial for the cause and cure of bacterial vaginosis, and Gedea Biotech AB is driving groundbreaking research in this area in close collaboration with Karolinska Institutet.   Emilia Lahtinen is a Industrial Doctoral Student for Gedea at Center for Translational Microbiome Research at Karolinska Institutet and in her PhD project, she is using advanced sequencing techniques coupled with computational pipelines, machine learning and mathematical modelling to determine the microbial etiology of bacterial vaginosis and factors associated with successful, antibiotic-free treatment with pHyph.   This Monday, she had her half-time seminar with her project "The microbiome response to treatments of bacterial vaginosis" where she has analyzed the effect of pHyph in women with bacterial vaginosis.     Annette Säfholm, Sten Kornfält and Helena Strevens represented Gedea at the seminar and were all very impressed by Emilias great knowledge in her field. - Emilia did a fantastic job answering all questions on a range of topics, including bioinformatics methods, the vaginal microbiome, diagnosis of bacterial vaginosis, antibiotic resistance, and the design of clinical studies, says Annette Säfholm.

We are pleased to welcome Hilda Ahnstedt as a Grant Specialist at Gedea Biotech AB Hilda has extensive experience working with research grants as Program Manager at the University of Texas Health Science Center at Houston. She has also conducted her own research on sex differences in healthcare and health and has a strong commitment to women's health.

Today we had the pleasure to present Gedea Biotech AB to the great audience in Medicon Village at the Science for breakfast event. Sten Kornfält and Eva Norell explained why bacterial vaginosis is so limiting for the affected women and how Gedea's product pHyph can transform treatment for vaginal infections. Our message is that women need a treatment for bacterial vaginosis that they can trust; for cure and for keeping them well for the long term. #womensheath #AMR #mediconvillage

Gedea Biotech is developing a treatment for vaginal infections that actually works, meaning an effective, antibiotic free and safe treatment for vaginal infections that treats the infection and minimizes the risk of recurrence. Meet one of our colleagues, Sten Kornfält, Clinical Project Manager What is your role at Gedea? I have been with Gedea for five years now and I’m responsible for our clinical investigations. Together with the team at Gedea I plan and design the investigations, and when the clinical projects are ongoing, I also manage them together with our CRO (Clinical Research Orgionization). When the studies are completed, I’m involved in the evaluation of the results.   What previous positions have you had? I have long experience working with clinical trials at different CROs, both as a Clinical Research Associate and as Project Manager.   What makes your job particularly meaningful? BV and VVC are huge burdens for many women and our product will make a difference for them. The product is safe and helps the microbiome to restore in a natural way. To help document this product and make it available on the market feels very meaningful.   Is there anything that is frustrating and testing your patience in your work? Clinical investigations take a long time to complete, and there are a lot of hurdles. Solving the problems is however also stimulating.   What is the next milestone or achievement in your work at Gedea? Gedea Biotech has a comprehensive and ambitious clinical program. It is important for us that the advantages of our product are thoroughly documented. We also want to understand what is happening in the vaginal microbiome in women that have BV or VVC, and how our product may positively alter the conditions that have caused the infections. The next milestone will be the completion of NEFERTITI-2 study in bacterial vaginosis. 

Gedea Biotech is developing a treatment for vaginal infections that actually works, meaning an effective, antibiotic free and safe treatment for vaginal infections that treats the infection and minimizes the risk of recurrence. Meet one of our colleagues, Per-Ola Forsberg, Chief Financial Officer   How long have you worked with Gedea? I started quite recently so only from April this year What previous positions have you had? I have 30 years of experience in pharmaceuticals and biotech industry and previous assignments include roles such as CFO at Idogen, LIDDS, Lund University Bioscience and Probi. At Probi, I was for a time vice president, with responsibility for the company's business operations. I have previously also held positions such as controller at Rexam Beverage Can Fosie and Head of Administration at PolyPeptide Laboratories, a subsidiary of Ferring.   What makes you feel meaning in your work? To be part of a development company with the aim of improving people's health. I think, if we do not make these efforts, possible interesting products will never reach the shelf and become available to patients or consumers. It gives me an energy to be involved in driving development companies forward.   Is there anything that is frustrating and testing your patience in your work? Clinical results and optimal product design are both moving targets, since demands from the market can vary and change over time. We have to be on our toes to keep up with these changes to have a strong offer.     What is the next milestone or achievement in your work at Gedea? From my point of view, MDR approval and thus CE marking for Europe is the next big milestone for Gedea Biotech and along the way results in our ongoing clinical trial support these approvals.